Michael Jeffers

7.5k total citations · 1 hit paper
78 papers, 5.7k citations indexed

About

Michael Jeffers is a scholar working on Molecular Biology, Hepatology and Oncology. According to data from OpenAlex, Michael Jeffers has authored 78 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 26 papers in Hepatology and 25 papers in Oncology. Recurrent topics in Michael Jeffers's work include Liver physiology and pathology (20 papers), Fibroblast Growth Factor Research (15 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Michael Jeffers is often cited by papers focused on Liver physiology and pathology (20 papers), Fibroblast Growth Factor Research (15 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Michael Jeffers collaborates with scholars based in United States, Germany and Japan. Michael Jeffers's co-authors include George F. Vande Woude, Sing Rong, Henri S. Lichenstein, Shahriar Koochekpour, Craig P. Webb, William J. LaRochelle, Xiaozhong Qian, James H. Resau, Ferenc Boldog and Yasuhiro Mitsuuchi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Michael Jeffers

77 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

2007 599 citations Michael Jeffers, Ferenc Boldog et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Jeffers United States	36	3.4k	1.7k	1.6k	997	770	78	5.7k
Martina Olivero Italy	33	3.0k 0.9×	2.6k 1.5×	1.5k 0.9×	813 0.8×	743 1.0×	80	5.6k
Carla Boccaccio Italy	33	2.1k 0.6×	1.3k 0.8×	1.4k 0.9×	809 0.8×	518 0.7×	63	4.2k
Maria Flavia Di Renzo Italy	40	4.0k 1.2×	3.5k 2.0×	1.9k 1.2×	995 1.0×	959 1.2×	106	7.4k
Nathalie Wong Hong Kong	46	4.6k 1.3×	843 0.5×	1.6k 0.9×	3.0k 3.0×	566 0.7×	120	7.4k
Yunfei Yuan China	51	4.8k 1.4×	1.6k 1.0×	1.7k 1.0×	3.7k 3.7×	837 1.1×	187	8.2k
Marshonna Forgues United States	36	5.5k 1.6×	2.0k 1.2×	2.5k 1.5×	3.9k 3.9×	948 1.2×	51	9.4k
Chen‐Yong Lin United States	38	2.5k 0.7×	912 0.5×	765 0.5×	1.2k 1.2×	304 0.4×	96	5.1k
Betty L. Slagle United States	33	4.0k 1.2×	1.0k 0.6×	3.4k 2.1×	1.3k 1.3×	202 0.3×	54	6.7k
Mark Merchant United States	32	3.1k 0.9×	427 0.3×	1.6k 1.0×	591 0.6×	645 0.8×	64	4.9k
Teresa L. Burgess United States	29	2.6k 0.8×	571 0.3×	1.3k 0.8×	385 0.4×	335 0.4×	44	4.1k

Countries citing papers authored by Michael Jeffers

Since Specialization

Citations

This map shows the geographic impact of Michael Jeffers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Jeffers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Jeffers more than expected).

Fields of papers citing papers by Michael Jeffers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Jeffers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Jeffers. The network helps show where Michael Jeffers may publish in the future.

Co-authorship network of co-authors of Michael Jeffers

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Jeffers. A scholar is included among the top collaborators of Michael Jeffers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Jeffers. Michael Jeffers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brose, Marcia S., et al.. (2019). Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial. Clinical Cancer Research. 25(24). 7370–7380. 14 indexed citations

Chaturvedi, Anuhar, Charu Gupta, Razif Gabdoulline, et al.. (2017). Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia. Blood. 130. 1352–1352. 8 indexed citations

Zhu, Andrew X., Yoon‐Koo Kang, Olivier Rosmorduc, et al.. (2016). Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research. 22(19). 4870–4879. 22 indexed citations

Rudolph, Marion, Tobias Anzeneder, Georg Beckmann, et al.. (2016). AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer. 16(1). 622–622. 66 indexed citations

Lim, Ho Yeong, Jeong Heo, Hye Jin Choi, et al.. (2014). A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research. 20(23). 5976–5985. 86 indexed citations

Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations

Eisen, Tim, Heikki Joensuu, Paul Nathan, et al.. (2012). Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. The Lancet Oncology. 13(10). 1055–1062. 84 indexed citations

Conway, Catherine, Alan Hanley, Anthony O’Grady, et al.. (2010). Image analysis as an adjunct to manual HER‐2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology. 57(1). 27–38. 54 indexed citations

Grauslund, Morten, Thomas Litman, Laura S. Collins, et al.. (2008). Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Molecular Cancer. 7(1). 70–70. 35 indexed citations

10.

Woude, George F. Vande, et al.. (2007). Met–HGF/SF: Tumorigenesis, Invasion and Metastasis. Novartis Foundation symposium. 212. 119–132. 34 indexed citations

11.

Qian, Xiaozhong, William J. LaRochelle, Gulshan Ara, et al.. (2006). Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Molecular Cancer Therapeutics. 5(8). 2086–2095. 117 indexed citations

12.

Dhanabal, Mohanraj, Michael Jeffers, William J. LaRochelle, & Henri S. Lichenstein. (2005). Angioarrestin: A unique angiopoietin-related protein with anti-angiogenic properties. Biochemical and Biophysical Research Communications. 333(2). 308–315. 20 indexed citations

13.

Jeffers, Michael, William F. McDonald, Meijia Yang, et al.. (2002). A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology. 123(4). 1151–1162. 57 indexed citations

14.

LaRochelle, William J., Michael Jeffers, William F. McDonald, et al.. (2001). PDGF-D, a new protease-activated growth factor. Nature Cell Biology. 3(5). 517–521. 300 indexed citations

15.

Ferrer‐Miralles, Neus, Antonio García‐España, Michael Jeffers, & Àngel Pellicer. (1999). The unr Gene: Evolutionary Considerations and Nucleic Acid-Binding Properties of Its Long Isoform Product. DNA and Cell Biology. 18(3). 209–218. 15 indexed citations

16.

Jeffers, Michael, et al.. (1999). Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor. Journal of Biological Chemistry. 274(23). 16377–16386. 83 indexed citations

17.

Rulong, Shen, et al.. (1998). CLINOSTAT ROTATION PROMOTES HGF/SF-INDUCED MORPHOGENESIS OF RAT PANCREATIC OVAL CELLS. 35(2). 55–61. 3 indexed citations

18.

Jeffers, Michael, Gregory A. Taylor, K. Michael Weidner, Satoshi Ōmura, & George F. Vande Woude. (1997). Degradation of the Met Tyrosine Kinase Receptor by the Ubiquitin-Proteasome Pathway. Molecular and Cellular Biology. 17(2). 799–808. 189 indexed citations

19.

Jeffers, Michael, et al.. (1996). Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.. PubMed. 13(4). 853–6. 101 indexed citations

20.

Rong, Sing, Michael Jeffers, James H. Resau, et al.. (1993). Met expression and sarcoma tumorigenicity.. PubMed. 53(22). 5355–60. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact